BR112014015329A2 - dispositivos de liberação de droga transmucosa para uso em alívio de dor crônica - Google Patents

dispositivos de liberação de droga transmucosa para uso em alívio de dor crônica

Info

Publication number
BR112014015329A2
BR112014015329A2 BR112014015329A BR112014015329A BR112014015329A2 BR 112014015329 A2 BR112014015329 A2 BR 112014015329A2 BR 112014015329 A BR112014015329 A BR 112014015329A BR 112014015329 A BR112014015329 A BR 112014015329A BR 112014015329 A2 BR112014015329 A2 BR 112014015329A2
Authority
BR
Brazil
Prior art keywords
chronic pain
drug delivery
transmucosal drug
delivery devices
pain relief
Prior art date
Application number
BR112014015329A
Other languages
English (en)
Other versions
BR112014015329A8 (pt
Inventor
Finn Andrew
Vasisht Niraj
Original Assignee
Biodelivery Sciences Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodelivery Sciences Int Inc filed Critical Biodelivery Sciences Int Inc
Publication of BR112014015329A2 publication Critical patent/BR112014015329A2/pt
Publication of BR112014015329A8 publication Critical patent/BR112014015329A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

resumo patente de invenção: "dispositivos de liberação de droga transmucosa para uso em alívio de dor crônica". são aqui providos métodos para tratamento de dor crônica através de administração de baixas doses de buprenorfina duas vezes por dia (ou uma vez por dia) através de um dispositivo de liberação de droga transmucosa. os métodos e dispositivos tratam eficientemente dor crônica sem significantes efeitos colaterais.
BR112014015329A 2011-12-21 2012-12-21 dispositivos de liberação de droga transmucosa para uso em alívio de dor crônica BR112014015329A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578755P 2011-12-21 2011-12-21
PCT/US2012/071330 WO2013096811A2 (en) 2011-12-21 2012-12-21 Transmucosal drug delivery devices for use in chronic pain relief

Publications (2)

Publication Number Publication Date
BR112014015329A2 true BR112014015329A2 (pt) 2017-06-13
BR112014015329A8 BR112014015329A8 (pt) 2017-06-13

Family

ID=48669710

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015329A BR112014015329A8 (pt) 2011-12-21 2012-12-21 dispositivos de liberação de droga transmucosa para uso em alívio de dor crônica

Country Status (16)

Country Link
EP (1) EP2793870A4 (pt)
JP (1) JP6255349B2 (pt)
KR (4) KR20190110628A (pt)
CN (2) CN110123792A (pt)
AU (4) AU2012358308A1 (pt)
BR (1) BR112014015329A8 (pt)
CA (1) CA2859859A1 (pt)
EA (2) EA201992762A1 (pt)
HK (1) HK1203365A1 (pt)
IL (2) IL233075A0 (pt)
IN (1) IN2014DN06117A (pt)
MX (2) MX362217B (pt)
SG (3) SG10201710667YA (pt)
UA (1) UA118540C2 (pt)
WO (1) WO2013096811A2 (pt)
ZA (1) ZA201804381B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
CN1423559A (zh) * 2000-02-08 2003-06-11 欧罗赛铁克股份有限公司 包含阿片样激动剂和拮抗剂的控释组合物
EP1389621A4 (en) 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
BRPI0619806A2 (pt) 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc dispositivo para fornecimento de fármacos transmucosal resistente ao abuso
CA2649107A1 (en) 2006-04-12 2007-10-25 Spinal Motion, Inc. Posterior spinal device and method
KR101329496B1 (ko) * 2006-07-21 2013-11-13 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
GB0620661D0 (en) * 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CN105833420A (zh) * 2008-06-23 2016-08-10 生物递送科学国际公司 多向粘膜给药装置及使用方法
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Also Published As

Publication number Publication date
KR20220047889A (ko) 2022-04-19
JP2015500886A (ja) 2015-01-08
UA118540C2 (uk) 2019-02-11
HK1203365A1 (en) 2015-10-30
IN2014DN06117A (pt) 2015-08-14
EA201992762A1 (ru) 2020-07-31
MX2014007350A (es) 2014-09-15
SG11201403075XA (en) 2014-07-30
KR102026321B1 (ko) 2019-09-27
MX2021012154A (es) 2021-11-03
AU2019202602A1 (en) 2019-05-02
AU2017258916A1 (en) 2017-11-30
AU2021202042A1 (en) 2021-04-29
CN110123792A (zh) 2019-08-16
IL233075A0 (en) 2014-07-31
AU2012358308A1 (en) 2014-07-24
ZA201804381B (en) 2022-12-21
SG10202012743WA (en) 2021-01-28
MX362217B (es) 2019-01-09
CA2859859A1 (en) 2013-06-27
AU2017258916B2 (en) 2019-01-17
WO2013096811A3 (en) 2014-07-24
KR20140106720A (ko) 2014-09-03
EP2793870A2 (en) 2014-10-29
CN104125828A (zh) 2014-10-29
EA201491046A1 (ru) 2014-11-28
EA034529B1 (ru) 2020-02-18
KR20210003313A (ko) 2021-01-11
KR20190110628A (ko) 2019-09-30
WO2013096811A2 (en) 2013-06-27
IL285091A (en) 2021-08-31
EP2793870A4 (en) 2016-02-17
JP6255349B2 (ja) 2017-12-27
SG10201710667YA (en) 2018-02-27
BR112014015329A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
IN2015DN00450A (pt)
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
BR112012000862A8 (pt) composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2014153385A3 (en) Methods of treating metabolic disorders
BR112013029182A2 (pt) método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
PH12015502655A1 (en) Method
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2015013912A (es) Metodos y composiciones que utilizan 4-amino-2-(2,6-dioxo-piperidi n-3-il)-isoindolin-1,3-diona para tratamiento y manejo de canceres en el sistema nervioso central.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2018002681A (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
BR112014015329A2 (pt) dispositivos de liberação de droga transmucosa para uso em alívio de dor crônica
GB201115977D0 (en) Neurodevelopmental disorders
BR112013017829A2 (pt) método de tratamento de um paciente com sintomas de prostatite e/ou síndrome da dor pélvica e método de tratamento de um paciente com sintomas de prostatite crônicas/síndrome de dor pélvica crônica
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
EA201590760A1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]